US 11,951,229 B2
Liquid hemostatic medical material
Hirotsugu Kido, Sendai (JP); Katsunori Chiba, Sendai (JP); Hironori Arima, Osaka (JP); and Kenji Ohata, Osaka (JP)
Assigned to AOBAKASEI KABUSHIKI KAISHA, Miyagi (JP); and OSAKA CITY UNIVERSITY IN UNIVERSITY PUBLIC CORPORATION OSAKA, Miyagi (JP)
Filed by AOBAKASEI KABUSHIKI KAISHA, Sendai (JP); and OSAKA CITY UNIVERSITY IN UNIVERSITY PUBLIC CORPORATION OSAKA, Osaka (JP)
Filed on Aug. 20, 2021, as Appl. No. 17/407,982.
Claims priority of application No. 2020-139696 (JP), filed on Aug. 20, 2020; and application No. 2021-104461 (JP), filed on Jun. 23, 2021.
Prior Publication US 2022/0054701 A1, Feb. 24, 2022
Int. Cl. A61L 26/00 (2006.01)
CPC A61L 26/0038 (2013.01) [A61L 26/0004 (2013.01); A61L 26/0023 (2013.01); A61L 26/0047 (2013.01); A61L 2400/04 (2013.01)] 5 Claims
OG exemplary drawing
 
1. A liquid medical material comprising:
a gelatin aqueous solution including calcium at a concentration of 0.2 M or more and 1.0 M or less, and gelatin having a concentration of 5% by weight or more and 40% by weight or less, an average molecular weight of 80,000 or more and 120,000 or less, and a molecular weight distribution of 20,000 or more and 300,000 or less;
transglutaminase configured to induce crosslinking of the gelatin; and
porous dextran having a DE value of 10 or more and 25 or less, and an average molecular weight of 5000 or more and 25000 or less,
wherein the calcium includes a compound selected from the group consisting of calcium chloride and calcium carbonate wherein the liquid material is hemostatic material.